The Roche group said that its cancer drug, Xeloda (capecitabine) has been approved in Europe in combination with the chemotherapy drug, oxaliplatin, for the adjuvant treatment of patients with early colon cancer. The combination is called Xelox.
An experimental lung cancer drug that was strategically important to both Novartis and Antisoma Plc has run into what looks to be an insurmountable obstacle.
Neuropharm Group Plc, whose investigational treatment for autism failed to show efficacy at Phase 3, is exploring a voluntary liquidation and a return of cash to shareholders. The UK company is listed on AIM.
Thomas Klaue, chief financial officer of MediGene AG since 2007, is leaving the company following differences with other members of the management team over strategy.
Evotec AG is on course to achieve profitability in 2012, according to a company statement released in connection with its 2009 results.
A team of researchers from North America has shown that it is possible to reverse the process of aging in certain induced pluripotent stem cells (iPS), potentially increasing their usefulness as future therapies for age-related degenerative disease.
AstraZeneca Plc has concluded a collaborative research agreement with the University of Pennsylvania in the US to generate new drug candidates for Alzheimer’s disease. Financial details were not disclosed.
The European Medicines Agency is recommending that the cancer drug, Tarceva (erlotinib), be approved for maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer. This represents a new treatment option.
Neovacs SA, a privately-held company with a novel therapy for treating arthritis and several other diseases, is making an initial public offering (IPO) of its shares on the NYSE-Euronext in Paris.
Cancer Research Technology (CRT), the technology transfer arm of the charity, Cancer Research UK, has reached an agreement with Cephalon Inc of the US to develop new small molecule drugs targeting members of the protein kinase C family.